JBS (JBS) Q3 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q3 2026 earnings summary
11 Nov, 2026Executive summary
Q3 revenue rose ~1% YoY, while adjusted EBITDA and net income declined amid cattle-cost pressure, weaker pork and poultry margins, and challenging trade flows.
U.S. beef returned to positive Q3 adjusted EBITDA under U.S. GAAP; leverage rose to 3.54x as cash generation and deleveraging remained priorities.
Financial highlights
Q3 IFRS net revenue was $22.738B vs. $22.597B; gross profit was $2.41B vs. $2.97B, operating profit $516M vs. $1.22B, and attributable net income $164M vs. $581M.
IFRS adjusted EBITDA was $1.001B, with a 4.4% margin; U.S. GAAP adjusted EBITDA was $1.181B, with a 5.2% margin. Adjusted net income was $167M and EPS $0.16.
Q3 free cash flow was negative $167M, down $551M YoY; higher Brazil working capital use was partly offset by positive contributions from U.S. and Australia units.
9M revenue rose 8.1% to $68.2B, while net income fell 81.4% to $334.3M and Adjusted EBITDA declined 26.8% to $3.7B.
Outlook and guidance
Early-Q4 China demand and preparations for the 2027 quota supported a more favorable Brazil beef export outlook; seasonal demand and October improvement also supported expectations.
Seara expected higher Q4 margins QoQ, supported by seasonal demand, a weaker real, exports and sales of poultry inventories held in Europe.
U.S. beef Q4 was expected to improve; management anticipated a better 2027 market and cited potential operational-efficiency and sales-synergy gains of up to or above 2 percentage points.
U.S. pork conditions were expected to remain difficult through H1 2027, with possible improvement in H2 as global production adjusts; recovery timing remained uncertain.
A 2026 cash-flow exercise estimated $5.5B, including $2.1B CapEx and $550M working-capital consumption; a 2027 scenario anticipated leverage below 3x with $5.5B–$6B EBITDA and a beef turnaround.
Latest events from JBS
- Global protein leader with $91.2B revenue, rising margins, and strong global diversification.JBS
Institutional presentation - Record Q2 sales of $24B and improved cash flow offset by margin pressure and a net loss.JBS
Q2 2026 - Sustainable growth, margin expansion, and global diversification drive strong returns.JBS
Investor Day 2026 presentation - Global protein leader with $88.3B revenue, margin growth, and expanding global footprint.JBS
Investor presentation - Global protein leader with $88.3B revenue, expanding through diversification and strategic investment.JBS
Investor presentation - Net sales up 11% to $21.6B–$22B, but EBITDA and net income declined; leverage at 2.77x.JBS
Q1 2026 - Record $86.2B revenue and $2.02B net income in 2025, with margin pressure in North America.JBS
Q4 2025 - Record 3Q24: $19.9B revenue, $2.2B EBITDA, $693M profit, leverage at 2.15x.JBS
Q3 2024 - Q2 2024 saw record margins, $329M net profit, and strong cash flow, led by poultry and pork.JBS
Q2 2024